CENTER FOR PHARMACOECONOMICS
A division of MEDACorp
Insight and Perspective on the Health and Economic Impact of Innovations
Request Our ContentWe evaluate the health and economic impact of healthcare innovations on patients, caregivers, the health system, and society.
The Leerink Center for Pharmacoeconomics (CPE) conducts health economic evaluations for novel healthcare treatments. Our approach considers not only the healthcare costs and health benefits of novel treatments but also incorporates the broader impacts on patients and society.
In our reports, we extrapolate and synthesize evidence to quantify the health and economic impacts of healthcare innovations, share insights on key drivers of efficiency, and offer a reference point for how a product might perform under various cost‑effectiveness frameworks and assumptions. Through our podcasts and commentaries, we provide a perspective around health system efficiency, incentives for innovation, and the evolving landscape of drug pricing.
Our goal is to support companies and company builders as they plan their evidence‑generation strategies and consider the societal value of their products in development.
Recent CPE Content
Speak With Us
Reach out to your Leerink representative if you are interested in discussing the potential health and economic impacts from one of your healthcare innovations with the Leerink Center for Pharmacoeconomics.
-
What We Do
Evaluate Innovation: We build economic models for novel healthcare treatments using innovative methods to inform companies and company builders of the key drivers of societal value and how a product might perform under different cost-effectiveness analysis frameworks.
Engage Clients: We talk with companies and company builders about the potential health and economic impacts of their products and the evidence needs to support a strong health economic proposition.
Explain the Industry: We provide commentary and host a podcast about health system efficiency, incentives for innovation, and the evolving landscape of drug pricing.
Leerink Center for Pharmacoeconomics Leadership
Melanie (Mel) Whittington is a Managing Director and Head of the Center for Pharmacoeconomics where she leads efforts to evaluate the health and economic impacts of healthcare innovations in the United States. She offers insight and perspective on the evidence needed to support strong health economic value propositions and the potential impact of novel cost-effectiveness analysis frameworks. As a thought leader in health economics, she provides commentary on health system efficiency, incentives for innovation, and the evolving landscape of drug pricing. She also hosts the Perspectives by the Leerink Center for Pharmacoeconomics podcast.
Dr. Whittington is also a Senior Fellow within the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, is on the Panel of Health Advisers for the Congressional Budget Office, and is an Advisory Board member for the Incubate Coalition. She has published more than 70 peer-reviewed articles.
Prior to joining MEDACorp in 2024, Dr. Whittington was the Managing Director and Founder of Valusphere, a health economics consultancy that developed economic evaluations, advised on value demonstration, and provided training to value assessment stakeholders. Prior to Valusphere, Dr. Whittington was the Director of Health Economics at the Institute for Clinical and Economic Review and was faculty within the School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus.
Dr. Whittington earned a BS in Biological Sciences from the University of Missouri, an MS in Health Sciences from Western Illinois University, and a PhD in Health Services Research from the University of Colorado Anschutz Medical Campus.
